When it comes to allergy and asthma relief, no organization is better prepared to inform sufferers of potential treatments or dangers than the U.S. Food and Drug Administration (FDA). Regularly, it will release a list of recently approved medications and drugs available to consumers or ones that will be in circulation in the near future. Additionally, they also release warnings for consumers regarding existing products, ingredients and potential side effects.
Not long ago, the FDA released warning of the effects that a legume called lupin could have on tree nut and peanut allergy sufferers. The product, the organization reports, could cause anaphylaxis, hives, swelling of the lips, breathing difficulties and vomiting. However, lupin is not the only product that the allergy conscious should be aware of.
The FDA has also warned asthmatics to be wary of a new product that is intended to help patients with chronic obstructive pulmonary disease (COPD). Developed by Boehringer Ingelheim Pharmaceuticals, Olodaterol, also known as Striverdi Respimat, works as a long-acting beta-adrenergic agonist (LABA) to allow muscles around the lungs to remain relaxed. While this product may be beneficial to COPD patients, it is also a cause for increased risk of asthma-related deaths.
"The safety and effectiveness of Striverdi Respimat in people with asthma has not been established, and it is not approved to treat asthma," according to the press release issued by the pharmaceutical company. "Striverdi Respimat should not be used as a rescue therapy to treat sudden breathing problems (acute bronchospasm)."
For allergy and asthma sufferers, being aware of both treatments and potential dangers is critical in leading a safe and healthy lifestyle. For the best practices in allergy prevention, follow along with this blog. If you are interested in learning more about any of our products, contact Allergy Be Gone Today.
